EP3307357B2 - Dispositif de collecte de donnees destine a etre fixe a un dispositif d'injection - Google Patents

Dispositif de collecte de donnees destine a etre fixe a un dispositif d'injection Download PDF

Info

Publication number
EP3307357B2
EP3307357B2 EP16729241.6A EP16729241A EP3307357B2 EP 3307357 B2 EP3307357 B2 EP 3307357B2 EP 16729241 A EP16729241 A EP 16729241A EP 3307357 B2 EP3307357 B2 EP 3307357B2
Authority
EP
European Patent Office
Prior art keywords
data collection
collection device
injection device
medicament
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16729241.6A
Other languages
German (de)
English (en)
Other versions
EP3307357A1 (fr
EP3307357B1 (fr
Inventor
Maurice Toporek
Marcus-Meinolf DITTRICH
Christian Nessel
Stephan Riedel
Armin Koller
Alexander Heinrich
Florian EBERLI
Philipp Müller
Sven Zwicker
Matthias Felber
Christoph Matthias GUGL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131518&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3307357(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP15171252.8A external-priority patent/EP3103492A1/fr
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to EP19209180.9A priority Critical patent/EP3656423B1/fr
Priority to EP23208919.3A priority patent/EP4316552A3/fr
Priority to PL16729241.6T priority patent/PL3307357T5/pl
Publication of EP3307357A1 publication Critical patent/EP3307357A1/fr
Publication of EP3307357B1 publication Critical patent/EP3307357B1/fr
Application granted granted Critical
Publication of EP3307357B2 publication Critical patent/EP3307357B2/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31545—Setting modes for dosing
    • A61M5/31548—Mechanically operated dose setting member
    • A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
    • A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31525—Dosing
    • A61M5/31528—Dosing by means of rotational movements, e.g. screw-thread mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
    • A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
    • A61M2005/3126—Specific display means related to dosing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3306—Optical measuring means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/587—Lighting arrangements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Definitions

  • the present invention relates to a data collection device for attachment to an injection device and collecting medicament dosage information therefrom.
  • Such injection can be performed by using injection devices, which are applied either by medical personnel or by patients themselves.
  • type-1 and type-2 diabetes can be treated by patients themselves by injection of insulin doses, for example once or several times per day.
  • a pre-filled disposable insulin pen can be used as an injection device.
  • a re-usable pen may be used.
  • a re-usable pen allows replacement of an empty medicament cartridge by a new one. Either pen may come with a set of one-way needles that are replaced before each use.
  • the insulin dose to be injected can then for instance be manually selected at the insulin pen by turning a dosage knob and observing the actual dose from a dose window or display of the insulin pen.
  • the dose is then injected by inserting the needle into a suited skin portion and pressing an injection button of the insulin pen.
  • an injection button of the insulin pen To be able to monitor insulin injection, for instance to prevent false handling of the insulin pen or to keep track of the doses already applied, it is desirable to measure information related to a condition and/or use of the injection device, such as for instance information on the injected insulin dose.
  • WO2014/037331 discloses a pen type injection device and electronic add-on monitoring module for monitoring and logging dose setting and administration.
  • the module comprises a main body part for attachment to a main body of the injection device, and an arm coupled to the main body part and slidable between an extended position and a retracted position, the arm having a physical parameter that varies along its length.
  • the module further comprises a sensor support provided on the arm, a sensor component rotatable with respect to the arm and coupled to rotate with a dosage knob of the injection device, and an arm parameter sensor.
  • the module further comprises a processor configured to use outputs of the rotatable component sensor and the arm parameter sensor to determine that a dose is dialed into the injection device.
  • a first aspect of the invention provides a data collection device comprising a first portion comprising a sleeve configured to attach the data collection device to an injection device by engaging a dosage knob of the injection device, a second portion rotatably attached to the first portion, the second portion configured to engage with a dose button of the injection device, a sensor arrangement configured to detect rotation of the first portion relative to the second portion during expulsion of a medicament by the injection device and a processor arrangement configured to, based on said detected movement, determine a medicament amount expelled by the injection device.
  • the data collection device may, optionally, be configured so that it does not obscure display of a currently programmed dosage, avoiding the need to provide an additional display of the dosage amount for viewing by the user.
  • the determination of the medicament dosage amount may be less computationally intensive than optical character recognition techniques.
  • the data collection device may be implemented in an embodiment wherein the second portion comprises an outer portion having first electrical contacts, the second portion comprises a inner portion having second electrical contacts and the inner portion is axially movable relative to the outer portion to engage said first electrical contacts with said second electrical contacts when pressure is applied to the outer portion. For instance, engagement of the first and second electrical contacts may activate the data collection device.
  • data collection device may comprise a piezo-electric generator arranged to power the data collection device when pressure is applied to the outer portion.
  • the data collection device may comprise a timer triggered when said first electrical contacts are engaged and/or disengaged from the second electrical contacts.
  • the data collection device may be configured to determine an elapsed time since the timer was last triggered and to generate an alert if the elapsed time is inconsistent with a threshold condition.
  • the data collection device have the processor arrangement configured to determine a time stamp for the administration of the medicament dosage using said timer and to store the determined medicament dosage and said time stamp.
  • the data collection device may have the processor arrangement configured to transmit a log of determined medicament dosages and time stamp information to another device.
  • the data collection device may be configured to switch between a first configuration in which rotation of the first portion relative to the second portion is prevented and a second configuration in which the first portion can be rotated relative to the second portion.
  • the second portion may be axially movable relative to the first portion to switch between said first configuration and said second configuration.
  • the data collection device may have the sensor arrangement comprising one or more of an optical sensor, a magnetic sensor, a capacitive sensor and a mechanical sensor.
  • the data collection device may comprise a transfer arrangement arranged to engage a rotatable component of the injection device wherein the first portion is configured to be attached to a rotatable component of the injection device and wherein the transfer arrangement is configured to rotate the first portion relative to the second portion when said rotatable component rotates.
  • the data collection device may have the transfer arrangement comprising a friction wheel.
  • a second aspect of the invention provides a medicament administration apparatus which comprises an injection device having a rotatable component configured to rotate as a medicament is expelled from the injection device and a data collection device as set out in the preceding sections.
  • the medicament administration apparatus may have the injection device comprising an injection button arranged to cause expulsion of the medicament from the injection device and may have the second portion being arranged to press on the injection button when pressure is applied to the second portion.
  • the medicament administration apparatus may comprise an injection device comprising a rotatable component configured to rotate as a medicament is expelled from the injection device; and a data collection device as set out before wherein the transfer arrangement is arranged to engage a rotatable sleeve of the injection device.
  • the injection device is a disposable injection device and the data collection device is configured to be releasably attachable to the injection device.
  • the injection device may be a reusable injection device and the data collection device configured to be permanently attached to the injection device.
  • the injection device may be an injector pen.
  • a third aspect of the invention provides a data collection device comprising:
  • the first portion may have an internal surface formed of a deformable material.
  • the first portion may have an internal surface shaped to correspond to external features of the dosage knob of the injection device.
  • the first portion may have an internal surface configured to mate with external features of the dosage knob of the injection device.
  • the internal surface of the first portion may include grooves that correspond in shape with formations on the surface of the dosage knob of the injection device.
  • the grooves may have mouths at an open end of the first portion and the grooves may taper to a narrower width away from the open end of the first portion.
  • the first portion may be provided with one or more external grip features to facilitate gripping of the first portion by a user to effect rotation of the data collection device relative to a housing of the injection device.
  • the user-accessible surface of the second portion may be larger than the user-accessible portion of the first portion when the data collection device is installed on the injection device.
  • the user-accessible surface of the first portion may be larger than the user-accessible portion of the second portion when the data collection device is installed on the injection device.
  • the second portion may be rotatably coupled with the first portion at a location that is closer radially to the longitudinal axis of the data collection device than it is to the outer diameter of the data collection device.
  • the second portion may be rotatably coupled with the first portion at a location that is radially further from the longitudinal axis of the data collection device than it is to the outer diameter of the data collection device, and optionally wherein the location is axially coincident with the location of the dosage knob when the data collection device is installed on the injection device.
  • the first portion may include an element configured to fit closely around a dose button of the injection device when the data collection device is coupled to the injection device.
  • the data collection device may be configured to switch between a first configuration in which rotation of the first portion relative to the second portion is prevented and a second configuration in which the first portion can be rotated relative to the second portion.
  • the sensor arrangement may comprise one or more of an optical sensor, a magnetic sensor, a capacitive sensor and a mechanical sensor.
  • the data collection device may further comprise an electrical switch configured to be operated upon movement of at least part of the second portion relative to the first portion, wherein a force required to operate the electrical switch is lower than a force required to cause medicament delivery from the injection device.
  • a fourth aspect of the invention provides a medicament administration apparatus which comprises an injection device comprising a rotatable component configured to rotate as a medicament is expelled from the injection device and a data collection device as above.
  • the injection device may comprise an injection button arranged to cause expulsion of the medicament from the injection device; and the second portion of the data collection device may be arranged to press on the injection button when pressure is applied to the second portion.
  • the injection device is a disposable injection device and the data collection device is configured to be releasably attachable to the injection device.
  • the injection device may be a reusable injection device and the data collection device configured to be permanently attached to the injection device.
  • the injection device may be an injector pen.
  • the present specification discloses a data collection device which is attachable to a proximal end of an injection device, such as a pen injector, such as to fit the injector device like a cap.
  • the data collection device is configured such that it can be push-fitted over a dosage knob or dose dialing knob of the injection device.
  • a first portion of the data collection device includes a cavity that receives the dosage knob, and includes a deformable inner surface such as to provide a tight fit over the dosage knob and/or has features that mate closely with external features of the dosage knob.
  • the data collection device can easily be installed on the injection device, and can easily be removed through application of a removal force between the data collection device and the injection device in an axial direction.
  • the data collection device When installed, the data collection device is manipulated by the user in order to effect operation of the injection device.
  • the data collection device when installed monitors quantities and times of medicament delivery from the injection pen. Medicament quantities can be transmitted, e.g. to a smartphone, and/or displayed on a display of the data collection device.
  • the data collection device By providing the data collection device with push-fit features, it can be located onto and used with a series of different injection devices and thus monitor a user's medicament treatment over multiple devices. Moreover, this can be achieved without impeding normal use of the injection device and without obscuring a dosage window of the injection device.
  • Figure 1 is an exploded view of a medicament delivery device.
  • the medicament delivery device is an injection device 1, such as Sanofi's SoloSTAR ® insulin injection pen.
  • the injection device 1 of Figure 1 is a pre-filled, disposable injection pen that comprises a housing 10 and contains an insulin container 14, to which a needle 15 can be affixed.
  • the needle is protected by an inner needle cap 16 and either an outer needle cap 17 or an alternative cap 18.
  • An insulin dose to be ejected from injection device 1 can be programmed, or 'dialed in' by turning a dosage knob 12, and a currently programmed dose is then displayed via dosage window 13, for instance in multiples of units.
  • the dosage may be displayed in so-called International Units (IU), wherein one IU is the biological equivalent of about 45.5 micrograms of pure crystalline insulin (1/22 mg).
  • IU International Units
  • Other units may be employed in injection devices for delivering analogue insulin or other medicaments. It should be noted that the selected dose may equally well be displayed differently than as shown in the dosage window 13 in Figure 1 .
  • the dosage window 13 may be in the form of an aperture in the housing 10, which permits a user to view a limited portion of a number sleeve 70 that is configured to move when the dosage knob 12 is turned, to provide a visual indication of a currently programmed dose.
  • the dosage knob 12 is rotated on a helical path with respect to the housing 10 when turned during programming.
  • the dosage knob 12 includes one or more formations 71a, 71b, 71c to facilitate attachment of a data collection device to be described hereinbelow.
  • the injection device 1 may be configured so that turning the dosage knob 12 causes a mechanical click sound to provide acoustical feedback to a user.
  • the number sleeve 70 mechanically interacts with a piston in insulin container 14.
  • the injection button 11 When needle 15 is stuck into a skin portion of a patient, and then injection button 11 is pushed, the insulin dose displayed in display window 13 will be ejected from injection device 1.
  • the needle 15 of injection device 1 remains for a certain time in the skin portion after the injection button 11 is pushed, a high percentage of the dose is actually injected into the patient's body. Ejection of the insulin dose may also cause a mechanical click sound, which is however different from the sounds produced when using dosage knob 12.
  • the dosage knob 12 is turned to its initial position in an axial movement, that is to say without rotation, while the number sleeve 70 is rotated to return to its initial position, e.g. to display a dose of zero units.
  • Injection device 1 may be used for several injection processes until either the insulin container 14 is empty or the expiration date of the medicament in the injection device 1 (e.g. 28 days after the first use) is reached.
  • injection device 1 before using injection device 1 for the first time, it may be necessary to perform a so-called "prime shot” to remove air from insulin container 14 and needle 15, for instance by selecting two units of insulin and pressing injection button 11 while holding injection device 1 with the needle 15 upwards.
  • a so-called "prime shot” to remove air from insulin container 14 and needle 15, for instance by selecting two units of insulin and pressing injection button 11 while holding injection device 1 with the needle 15 upwards.
  • the ejected amounts substantially correspond to the injected doses, so that, for instance the amount of medicament ejected from the injection device 1 is equal to the dose received by the user. Nevertheless, differences (e.g. losses) between the ejected amounts and the injected doses may need to be taken into account.
  • Figure 2 is a perspective view of one end of the injection device 1 when a data collection device 20 according to an example embodiment is attached.
  • the data collection device 20 includes a housing 21 and an end plate 22 with an optional display 22a.
  • the data collection device 20 may take one of a number of different forms, as described below and as shown in the drawings.
  • Figure 3 is a cross-sectional view of the data collection device 20 according to an embodiment, when attached to the injection device 1.
  • the data collection device 20 includes a first portion 23 and a second portion 24, where the first portion 23 is capable of rotational movement relative to the second portion 24.
  • the first portion 23 is a sleeve that is positioned over the dosage knob 12.
  • the first portion may have formations 19a, 19b, 19c that co-operate with the formations 71a, 71b, 71c on the dosage knob 12.
  • the arrangement is such that, when the first portion 23 is rotated by a user during programming of the dosage, the dosage knob 12 also rotates and such that, when the dosage knob 12 rotates during expulsion of medicament, the first portion 23 also rotates.
  • Resilient padding such as a foam rubber pad 44
  • a foam rubber pad 44 may be provided within the formations 19a-c on the first portion 23, to allow for tolerances in the dimensions of the formations 19a-c on the first portion 23 and the formations 71a, 71 b, 71 c on the dosage knob 12 and/or to provide an engagement between the first portion 23 and the dosage knob 12 so that rotation of the first portion 23 causes rotation of the dosage knob 12 and vice versa.
  • the resilient padding 44 may alternatively be made of another rubber or synthetic rubber material.
  • the resilient padding 44 may be provided around the entire circumference of the first portion 23, or it may be provided at intermittent locations.
  • the resilient padding 44 may be provided alternatively to formations 19a-c on the first portion 23.
  • the inner surface of the first portion 23 at the distal end 35 (lowermost in Figure 3 ) is substantially featureless.
  • the inner surface may be generally cylindrical in shape. It may alternatively be generally conical, being wider at the distal end. It may alternatively be generally dome-shaped, being wider at the distal end.
  • the first portion 23 comprises a resilient padding of sufficient thickness to render formations that co-operate with the formations 71a, 71b, and 71c on the dosage knob.
  • the padding is soft enough to conform to the surface of the dosage knob 12.
  • the padding is soft enough to conform to the formations on the surface of the dosage knob 12.
  • the resilient padding 44 may be provided in addition to formations on the inner surface of the first portion 23.
  • the padding 44 described above performs multiple functions.
  • the resilient padding 44 deforms to accommodate the dosage knob 12 within the cavity of the first portion. Friction provides a reactive force in response to insertion of the dosage knob 12 within the first portion 23. This provides tactile feedback to the user indicating that the data collection device 20 is being received over the dosage knob 12. Once the data collection device 20 is installed fully, further movement is prevented. This can be detected by the user through tactile feedback by providing the user with a step change from some relative movement to no relative movement as the proximal end of the dosage knob 12 abuts an abutting surface at the proximal end of the cavity in the first section 23 (see Figure 6 for instance).
  • the friction between the data collection device 20 and the dosage knob 12 causes the data collection device 20 to remain installed on the injection device 1. This can be achieved without any further mechanism to secure the data collection device 20 to the injection device, although the use of a further mechanism is not precluded.
  • the friction force needs to be overcome. This can be achieved by applying a strong pulling force, for instance of 30N or more, to the data collection device in the proximal direction.
  • the padding also provides sufficient engagement for transferring rotation force applied by the user between the first portion 23 and the dosage knob 12 during dose setting/programming.
  • the force is communicated by friction between the first portion 23 and the dosage knob 12.
  • the friction force acting between the first portion 23 and the dosage knob 12 in the rotational direction exceeds the force required to overcome the forces internal to the drug delivery device 1 by a factor of at least 5, or more advantageously at least a factor of 10, which helps to avoid slippage between the components.
  • the formations 19a-c on the inner surface may take the form of features that have a shape that mates with the shape of the formations 71a, 71b, 71c on the dosage knob 12.
  • the formations 19a-c on the inner surface may take the form of features that have a shape corresponding closely to the shape of the formations 71a, 71b, 71c on the dosage knob 12. Close correspondence in shape can allow good engagement between the first portion 23 and the dosage knob 12.
  • the choice of a material with a relatively high friction coefficient to form the inner surface of the first portion 23 contributes to providing a fit between the data collection device 20 and the dosage knob 12 that results in retention of the data collection device 20 on the injection device 1.
  • the optional use of a resilient material on the inner surface of the first portion 23 contributes further to retention of the data collection device 20 on the injection device 1.
  • the material of the inner surface of the first portion 23 need not be resilient.
  • the formations 19a-c on the resilient inner surface of the first portion 23 may take the form of ribs.
  • the ribs may have a triangular cross-section, or they may have a domed cross-section.
  • the ribs may be circumferential. Alternatively, they may be axially arranged.
  • Axial ribs advantageously number at least four times the number of formations 71a, 71b, 71 c on the dosage knob 12. This can help to ensure that the formations 71a, 71b, 71c on the dosage knob 12 can easily be received by the formations on the first portion 23 without requiring specific rotational alignment.
  • the formations 19a, 19b may take the form of ribs.
  • the formations 71a-c of the dosage knob fall between the formations/ribs 19a-c of the first portion 23.
  • the formations 19a, 19b here are configured such as to grip the surface of dosage knob 12 between the formations 71a-c when the data collection device 20 is installed fully onto the injection device 1.
  • the ribs 19a, 19b have a height in the radial direction that is equal to or greater than the radial height of the formations 71 on the dosage knob 12.
  • the ribs are spaced and numbered such that it is unlikely that a proximal end of the ribs will contact a distal end of the formations on the dosage knob 12 when the data collection device is being installed.
  • the spacing between adjacent ribs may be equal to an integer multiple of the spacing between adjacent formations 71 on the dosage knob 12.
  • the configuration and spacing of the ribs is such that if there is contact between a proximal end of a rib and a distal end of a formation on the dosage knob 12 when the data collection device is being installed, there is substantially identical contact between multiple ribs and multiple formations 71. When this happens, a small amount of rotational force, which may be provided by the ribs glancing off the formations, causes the ribs to be located between the formations 71 on the dosage knob 12.
  • the ribs may or may not be twisted with respect to the longitudinal axis of the data collection device 20.
  • there may be a relative twist between different formations 19a-c for instance one formation/rib 19a has a clockwise twist and the next formation/rib 19b has an anticlockwise twist.
  • the formations 71a-c of the dosage knob fall between the formations/ribs 19a-c of the first portion 23.
  • the first portion 23 is shaped such that there is substantially even engagement between the first portion 23 and the dosage knob 12 for the whole of the axial length of the dosage knob 12. This helps to ensure correct axial orientation of the data collection device 20 with the injection device 1. Axial orientation is provided because the shapes of the components are such that any incorrect orientation results in a corrective force being applied radially between the dosage knob 12 and the first portion 23 as they are mated together. Correct axial alignment is useful because it provides a better transmission of rotation force from the first portion 23 to the dosage knob 12 and because it provides better feedback to the user when dose delivery is performed. It also generally improves the experience of the user.
  • the first portion 23 may be formed with a rigid section surrounding at least part of the second portion 24 and a resilient section that surrounds at least part of the dosage knob 12, the rigid section providing a firm gripping surface for the user when mounting or removing the data collection device 20 onto or from the injection device 1 and the resilient section assisting in mounting the first portion 23 over the dosage knob 12 and providing sufficient engagement for transferring rotation between the first portion 23 and dosage knob 12 during programming and medicament expulsion.
  • the rigid section may be formed of a different material from the resilient section.
  • Such a first portion 23 may, optionally, also include formations 19a-c configured to co-operate with the formations 71a, 71b, 71c on the dosage knob 12, as described above, and/or resilient padding 44.
  • an indicator is provided on the data collection device.
  • the indicator may for instance be a groove, a nose or a printed feature.
  • the indicator facilitates alignment by the user of the data collection device with a nose of the injection device 1. However, in the embodiments shown in the drawings, no such alignment is needed.
  • the coupling between the first portion 23 and the dosage knob 12 does not include any moving parts.
  • the first portion 23 is coupled with the dosage knob 12 solely through a close fit, through friction between surfaces of the components, optionally assisted by deformation of a resilient material forming the coupling surface of the first portion 23.
  • the user may grip and rotate the first portion 23, since this will cause the dosage knob 12 of the injection device 1 to turn and, thereby, program the dosage amount.
  • the second portion 24 is a body located within the first portion 23, to which it is rotatably attached using bearings 25.
  • the second portion 24 includes an outer portion 26, which includes the endplate 22 and optionally a display 22a.
  • the second portion 24 also includes an inner portion 27.
  • the inner portion 27 overlies the injection button 11.
  • the outer portion 26 and the inner portion 27 are attached by a fixture 28 that prevents rotation relative to each other.
  • the outer portion 26 can be moved axially relative to the inner portion 27 and one or more resilient members, such as springs 29, may be provided to bias the outer portion 26 away from the inner portion 27.
  • the data collection device 20 is configured to detect axial movement of the outer portion 26 relative to the inner portion 27. Movement greater than a predetermined amount may be detected using a switch 53, for instance, as is described later in the specification.
  • first electrical contacts 30 are provided on the outer portion 26, while corresponding second electrical contacts 31 are provided on the inner portion 27.
  • the outer portion 26 moves axially towards the inner portion, establishing a connection between the first and second electrical contacts 30, 31. Further pressure on the endplate 22 causes the inner portion 27 to press against, and activate, the injection button 11.
  • the first and second electrical contacts 30, 31 provide a data connection between the processor arrangement 50 and display 22a when engaged.
  • the data collection device 20 may be arranged to have a first configuration, in which rotation of the first portion 23 relative to the second portion 24 is prevented, and a second configuration, in which such rotation is unimpeded.
  • the first portion 23 and the second portion 24 may be provided with lock formations such as a protrusion 40 on one of the first and second portions 23, 24 and a circumferential groove 41 and axial recess 42 on the other of the first and second portions 23, 24.
  • the protrusion 40 is located in the recess 42 and rotation is prevented.
  • the data collection device 20 may be switched to the second configuration by axial movement of the second portion 24 relative to the first portion 23, so that the protrusion 40 is located within the circumferential groove 41 and rotation is permitted.
  • Figure 6 is an isometric cutaway view of a first alternative data collection device 240, which is a variation of the data collection device 20.
  • Figures 7a to 7e are different views of a second alternative data collection device 220, which is another variation of the data collection device 20.
  • Figure 8 is a cross-sectional view of the second alternative data collection device 220 installed on the injection device.
  • the Figures 2 , 5 , 6 , 7 and 8 data collection devices have a common characteristic that the first portion 23 has a larger accessible surface area than does the second portion 24.
  • the data collection device 240 of Figure 6 includes a capsule 244, which is contained within the body of the data collection device 240.
  • the capsule 244 itself contains a power source 54 or battery, in the form of a coin cell in this example, and a printed circuit board (PCB) 242.
  • a communications interface 243 for instance a Bluetooth TM Low Energy chip or a Near Field Communications (NFC) chip. It also supports a switch 53 for detecting axial movement of the second portion 24.
  • the PCB 242 further supports a sensor arrangement 51, which is configured to detect rotation of the first portion 23 relative to the second portion 24.
  • the capsule 244 is fixed in rotation relative to the second portion 24 and rotates with the second portion 24 relative to the first portion 23 when the dose is being delivered.
  • the power source 54 provides power to the electronic components of the data collection device 240.
  • the power source 54 is located distally to the PCB 242.
  • the power source 54 is abutted by the distal end of the capsule 244 and by the PCB 242.
  • the first portion 23 has three key structural elements.
  • the first portion 23 may be formed as one part, or it may be formed of multiple parts that are connected together.
  • a first element 246 of the first portion 23 is configured to engage with the dialing knob 12. Aspects of the first element are described above, especially in relation to Figures 4a to 4d .
  • a second element 247 is configured to engage with the dose delivery button 11. In particular, the second element 247 is configured to fit closely around the dose delivery button 11. The second element 247 helps to ensure correct axial alignment of the data collection device 240 on the injection device 1.
  • the second element 246 may take the form of a ring.
  • the second element 247 may have a low friction inner surface, so as not to impede movement of the dose delivery button 11 in the distal direction.
  • the third element 248 is located at the proximal end of the first portion 23. The third element 248 extends radially inwardly. It also surrounds the second portion 24 in the radial direction.
  • the capsule 244 is movable in the axial direction within the cavity formed in the first portion 23.
  • the capsule 244 is restrained in the proximal direction at the periphery of the capsule 244 by the third element 248 of the first portion 23. In the distal direction, the capsule 244 abuts the dose button 11.
  • the second portion 24 is connected at its periphery to a proximal end of the capsule 244.
  • a pillar 245 is provided at the center of the second portion 24 and extends axially.
  • the pillar 245 is coincident with the switch 53, and may or may not contact it when no force in the distal direction is applied to the second portion 24.
  • the center of the second portion 24 is slightly deformable in the distal direction.
  • the switch 53 is configured to be operated upon movement of at least part of the second portion 24 relative to the first portion 23.
  • a force required to operate the switch 53 is lower than a force required to cause medicament delivery from the injection device 1.
  • the force required to operate the switch 53 may be about 2 N, or more generally between 1 and 5 N.
  • a user dials a dose into the injection device 1. This is achieved by the user rotating the first portion 23 of the data collection device 240. The rotational force is communicated to the dosage knob 12, which rotates also. The second portion 24 also rotates along with the first portion when the dose is being dialed. During dialing, the electronics on the PCB 242 are not powered.
  • the second portion 24 in order to start delivery of the dose, i.e. to cause injection.
  • the second portion 24 deforms slightly and the center of the second portion 24 moves in the distal direction more than the periphery of the second portion 24, or put another way the center of the second portion 24 moves axially relative to the periphery of the second portion and axially relative to the first portion.
  • This causes the pillar 245 to activate the switch 53.
  • This causes the electronics on the PCB 242 to be powered and thus activated. Further movement of the second portion 24 is communicated into movement of the capsule 244 within the first portion 23. This is communicated to movement of the dose button 11 in the distal direction.
  • the dosage knob 12 begins to rotate relative to the dose button 11 as the dose delivery button is moved in the distal direction by action of the user.
  • the dose delivery button 11 does not rotate relative to the housing 10 of the injection device 1, but the dosage button and the number sleeve 70 move helically (i.e. they move axially and rotate simultaneously).
  • the first portion 23 thus rotates relative to the second portion 24.
  • rotation of the first portion 23 relative to the second portion 24 ceases.
  • the amount of rotation that occurred indicates the delivered dose.
  • the amount of rotation is detected by the sensor 51, and this is used to calculate the delivered dose.
  • the delivered dose is then stored in memory, as is described below.
  • the Figure 6 data collection device is absent of a display, although a display for displaying a delivered dose may instead be provided.
  • the Figure 6 data collection device includes an optical indicator arrangement.
  • the optical indicator arrangement may be one or two light sources, such as light emitting diodes (not shown).
  • the optical indicator arrangement may be provided axially or peripherally on the proximal end face of the second portion 24, or on the circumference of the second portion 24 or the first portion 23, for instance.
  • the optical indicator arrangement is configured to provide feedback regarding a dwell period.
  • the optical indicator arrangement of the data collection device indicates that a dwell time period is in place.
  • the optical indicator arrangement starts blinking, that is being activated intermittently.
  • the frequency of blinking can change over the dwell period. For instance, at the start of the dwell period the frequency may be about 5Hz and at the end of the period the frequency may be about 1Hz.
  • the optical indicator arrangement may remain illuminated, to indicate the end of the sequence and the end of the dwell period.
  • the duration of the dwell period depends on the type of medicament.
  • the type of medicament or the dwell time may be communication to the data collection device, for instance from a mobile phone running an application that is configured to operate in conjunction with the data collection device.
  • the optical indicator arrangement is configured to provide feedback regarding a medicament dose having already been taken recently.
  • the data collection device checks when the last dose was delivered. The user may press the second portion 24 of the data collection device in order to initiate delivery of medicament or specifically to request information about the time since the last dose delivery.
  • the data collection device determines if the dose already taken notification is to be provided by observation of the switch 53, a current time and a time of the last dose delivery. If it is determined that no significant dose (e.g. larger than 2 units) was delivered in a certain time period, for instance the previous hour, the optical indicator arrangement indicates that delivery of medicament is permitted. For instance, the optical indicator arrangement may glow green for one second. If instead it is determined that a significant dose was delivered within the certain time period, the optical indicator arrangement may glow or flash an alert, for instance red in color.
  • the optical indicator arrangement is configured to provide feedback regarding end of life of the data collection device. When an error or another unsolvable issue as an empty battery is detected, the data collection device indicates this, for instance by operating the optical indicator arrangement to blinking in red for at least several hours.
  • spring force from within the injection device causes the dose button 11 to return the capsule 244 and the second portion 24 to the original position.
  • the data collection device 220 of Figure 7 is very similar to the data collection device of Figure 6 . However, a different mechanism retains the second portion 24 in the distal direction.
  • the injection device 1 is absent from Figures 7a to 7e , but is shown in Figure 8 .
  • a proximally located part 221 is a recess having a shape that corresponds well with the shape of the corresponding formation 17 on the dosage knob 12 in every dimension.
  • a distally located part 222 has a mouth that flares outwardly in the distal direction. The mouth of the part 222 serves to catch the proximal end of a formation 17 of the dosage knob 12 as the data collection device 240 is placed onto the injection device 1. The sides of the mouth then cause adjustment of the rotational alignment so that the formations 17 on the dosage knob 12 are guided into the proximally located part 221 of the formations 19a-c of the first portion 23.
  • the distally located part 222 of the formations 19a-cc on the first portion 23 are engaged in the radial direction with the formations 17 on the dosage knob 12. This helps to keep correct axial alignment of the data collection device 220 on the injection device 1 and helps to retain the data collection device 220 on the injection device through friction.
  • the second portion 24 includes the pillar 245.
  • the third element 248 of the first portion 23 includes a radially inwardly extending collar 225.
  • the capsule 244 includes an annular neck portion 224.
  • the neck portion 224 fits around the pillar 245 in a rotationally locked connection.
  • the pillar 245 can move in the distal direction relative to the capsule 244 by a small amount, to activate the switch 53 as the dose delivery procedure is commenced, but before dose delivery starts, but otherwise is not movable relative to the capsule 244.
  • the pillar 245 and the neck portion 224 have interoperating features that limit axial movement of the components relative to each other.
  • one or more protrusions 228 fit into one or more indents 229.
  • the movement of the second portion 24 relative to the capsule 244 is limited by the ends of the one or more indents 229 as regards the one or more protrusions 228.
  • the protrusions 228 are provided on the pillar 245 and the indents 229 are provided on the neck portion 224, but alternative arrangements will be envisaged by the skilled person.
  • a low friction surface is provided between the radially inward end of the collar 225 and the radially outward surface of the neck 224.
  • the second portion 24 is rotatably coupled with the first portion at a location that is closer radially to the longitudinal axis of the data collection device 240 than it is to the outer diameter of the data collection device.
  • the provision of the contact surfaces of the first portion 23 and the capsule 244/second portion 24 at a relatively radially inward positon is advantageous. In particular, it reduces the area of contact, which thus reduces friction.
  • less torque is required to rotate the first portion 23 and the second portion 24 relative to one another during dose delivery. This improves drug delivery and makes the combination of the injection device 1 and the data collection device 220 easier to use.
  • a slotted disc 249 allows the sensor 51 to detect the amount of rotation of the first portion 23 relative to the second portion 24.
  • a photodiode or other optical sensor 51 on one portion, for instance the second portion 24, is directed at the slotted disc 249, which rotates with the other portion, for instance the first portion 23.
  • the sensor 51 detects light which is reflected or transmitted by an amount that varies according to the position of the slots relative to the sensor 51 as the slotted disc 249 moves. Rotation of the slotted disc 249 relative to the sensor 51 thus causes the signal detected by the sensor to change.
  • the number of high intensity or low intensity pulses can be counted, to derive the amount of rotation.
  • High or low intensity pulses can be detected for instance using a threshold circuit.
  • the number of changes from low intensity to high intensity, or vice versa can be counted. Changes can be determined using a differentiator circuit, for instance. Counting the number of changes provides good reliability because it does not depend on a correct intensity threshold being used. In either case, the number of slots passing the sensor 51 is counted, and therefrom the dose delivered can be calculated.
  • the Figures 7 and 8 data collection device is absent of a display, although a display for displaying a delivered dose may instead be provided.
  • a user dials a dose into the injection device 1. This is achieved by the user rotating the first portion 23 of the data collection device 220. The rotational force is communicated to the dosage knob 12, which rotates also. The second portion 24 also rotates along with the first portion when the dose is being dialed. During dialing, the electronics on the PCB 242 are not powered.
  • the second portion 24 in order to start delivery of the dose, i.e. to commence injection.
  • the second portion 24 moves in the distal direction from one end to the other end of the distance permitted by interoperation of the one or more protrusions 228 fit into one or more indents 229.
  • the location of the second portion 24 activates the switch 53. This causes the electronics on the PCB 242 to be powered and thus activated. Further movement of the second portion 24 is communicated into movement of the capsule 244 within the first portion 23. This is communicated to movement of the dose button 11 in the distal direction.
  • the dosage knob 12 begins to rotate relative to the rest of the injection device 1, including the dose button 11.
  • the first portion 23 thus rotates relative to the second portion 24.
  • rotation of the first portion 23 relative to the second portion 24 ceases.
  • the amount of rotation that occurred indicates the delivered dose.
  • the amount of rotation is detected by the sensor 51, and this is used to calculate the delivered dose.
  • the delivered dose may then be displayed on the display 22a and/or stored in non-transient memory or transient memory, which may or may not be part of the processor arrangement.
  • spring force from within the injection device causes the dose button 11 to return the capsule 244 and the second portion 24 to the original position.
  • Figures 9a to 9e are different views of a third alternative data collection device 120, which is a variation of the data collection device 20.
  • Figures 10a to 10d are different views of a fourth alternative data collection device 140, which is a variation of the data collection device 20.
  • the Figures 9 and 10 data collection devices have a common characteristic that the second portion 24 has a larger user-contactable external surface area than does the first portion 23.
  • the shape of the second element 247 of the first portion 23, which serves to guide the data collection device to correct axial alignment using the dose button 11, is clearly visible in Figures 9a and 9e .
  • the dose button 11 is shown in a depressed state in Figure 9a so is not shown engaging the second element 247 of the first portion 23 in this Figure.
  • Second element 247 is shaped such that it at least partly fits around a dose button of the injection device when the data collection device is coupled to the injection device.
  • the second portion 24 is relatively large.
  • a spring 121 biases two power source (e.g. batteries) 54 against the distal face of the PCB 242.
  • a conductor 122 forms an electrical circuit between the proximal face of the proximal power source 54 and the PCB 242.
  • the switch 53 is formed on the proximal face of the PCB 242.
  • the switch 53 may include a spring terminal, as shown in the Figure. The spring terminal is moved, thereby to operate the switch 53, upon movement of the second portion 24 in the distal direction relative to the first portion 23.
  • a force required to operate the switch 53 is lower than the force required to cause medicament delivery from the injection device 1.
  • the components of the data collection device will thus be powered before dose delivery commences.
  • the force required to operate the switch 53 may be about 2 N, or more generally between 1 and 5 N.
  • a first collar 124 is directed in a distal direction from the distal end of the capsule 244.
  • a second collar 125 extends distally from the distal end of the capsule 244. The second collar 125 is outside of the first collar 124, and they are concentric.
  • the second collar 125 and the second portion 24 have interoperating features that limit axial movement of the components relative to each other.
  • one or more protrusions 228 fit into one or more indents 229.
  • the movement of the second portion 24 relative to the capsule 244 is limited by the ends of the one or more indents 229 as regards the one or more protrusions 228.
  • the protrusions 228 are provided on the second collar 125, and thus the capsule 244, and the indents 229 are provided on the second portion 24, but alternative arrangements will be envisaged by the skilled person.
  • the first collar 124 snugly fits the dose button 11, to assist in axial alignment between the data collection device 120 and the injection device 1 during delivery.
  • a washer (not shown) may be provided between the first collar 124 and the dose button 11, to improve contact between the components.
  • the first collar 124 does not contact the first portion 23 during installation of the data collection device 120 nor during dose delivery.
  • the first portion 23 is provided with grip features 123. These allow a user to grip the first portion so as to provide torque and thus rotate the first portion when setting a dose.
  • the grip features 123 provide surfaces that extend generally radially, to which the user can provide force to cause rotation of the first portion 23.
  • the first portion 23 is coupled to the second portion 24 by a connector arrangement 230, 231, 228.
  • the first portion 23 includes a first L section component 231, which has an abutting surface facing in the distal direction. This is formed as part of the first portion 23.
  • a second L section component 230 forming part of the second portion 24, is coupled to a support 232, which is coupled to the PCB 242, the first collar 124 and other components of the second portion 24.
  • the second L section component 230 has an abutting surface facing in the proximal direction.
  • the second L section component 230 and the other components that are coupled to it, are attached to the first section 23 during manufacture by application of a force to cause a snap fit such that the abutting surfaces of the first and second L section components 231, 230 are located together.
  • the snap fitting of the second L section component 230 over the first L section component 231 is facilitated by a sloping face of the first L section component 231, which faces slightly in the proximal direction.
  • the main body 234 of the second portion, with the third L section component 228 already fitted, is snap fitted over the second L section component 230.
  • the snap fitting is facilitated by a sloping face of the third L section component 228, which faces slightly in the distal direction.
  • a proximally facing abutting surface of the third L section component then abuts a distally facing abutting surface of the second L section component 228.
  • This arrangement keeps the spring 121 in compression, thereby ensuring good electrical connection of the power source 54. It also allows for a simple manufacturing process and the use of low cost components.
  • the two portions rotate relative to one another by a low friction contact between surfaces of the first and second L section components 230, 231.
  • the low friction contact may be provided by suitable coating of the relevant surfaces, or by suitable material choice of the components themselves.
  • force is applied in an axial direction.
  • the user is likely to apply force to the second portion 24.
  • the force is communicated to the first portion, to result in fitting of the first portion 23 over the dosage knob 12, by the distal end of the third L section component 228, or more generally the main body 234, against a proximally facing surface 235 of the first portion 23.
  • a spring force provided by the data collection device 120 forces the second portion 24 in the proximal direction relative to the first portion 23, after installation. This spring force is greater than a reaction force that is provided by the injection device 1 during dose delivery (the reaction force results primarily from friction from movement of internal components and hydrodynamic force resulting from medicament expulsion through the needle).
  • the distal end of the third L section component 228, or more generally the main body 234 does not contact the proximally facing surface 235 of the first portion 23 during dose delivery. If they were to be in contact during dose delivery, a friction force would oppose rotational movement between the first portion 23 and the second portion 24.
  • the Figure 9 data collection device 220 is absent of a display, although a display for displaying a delivered dose may instead be provided.
  • a user dials a dose into the injection device 1. This is achieved by the user rotating the first portion 23 of the data collection device 220. The rotational force is communicated to the dosage knob 12, which rotates also. The second portion 24 also rotates along with the first portion when the dose is being dialed. During dialing, the electronics on the PCB 242 are not powered.
  • the second portion 24 in order to start delivery of the dose, i.e. to cause injection.
  • the second portion 24 moves in the distal direction from one end to the other end of the distance permitted by interoperation of the one or more protrusions 228 and the one or more indents 229.
  • the location of the second portion 24 activates the switch 53. This causes the electronics on the PCB 242 to be powered and thus activated. Further movement of the second portion 24 is communicated into movement of the capsule 244 in the distal direction. This is communicated to movement of the dose button 11 in the distal direction.
  • the dosage knob 12 begins to rotate relative to the rest of the injection device 1, including the dose button 11.
  • the first portion 23 thus rotates relative to the second portion 24.
  • rotation of the first portion 23 relative to the second portion 24 ceases.
  • the amount of rotation that occurred indicates the delivered dose.
  • the amount of rotation is detected by the sensor 51, and this is used to calculate the delivered dose.
  • the delivered dose may then be displayed on the display 22a.
  • spring force from within the injection device causes the dose button 11 to return the capsule 244 and the second portion 24 to the original position.
  • the user is easily able to avoid contacting the first portion 23 when using the second portion 24 to cause dose delivery. This is the same regardless of whether the user uses their thumb or their index finger to manipulate the second portion 24.
  • the Figure 10 data collection device 140 is very similar to the Figure 9 data collection device 120.
  • the data collection device 141 includes a grip element 141 formed of a high friction material, instead of macro features 123, to provide a grip by which the user can dial a dose into the injection device.
  • the grip element 141 is in the form of a band.
  • the grip element is fitted into a groove 142 that is provided on the outside surface of the first portion 23.
  • the data collection device 140 is generally conical shaped.
  • the diameter of the data collection device 140 is greater at the proximal end than it is at the distal end. This further facilitates the user being able to avoid contacting the first portion 23 when using the second portion 24 to cause dose delivery. This is the same regardless of whether the user uses their thumb or their index finger to manipulate the second portion 24.
  • Figure 10b shows the slotted disc 249 that allows rotation of the first portion 23 relative to the second portion 24 to be detected and measured.
  • the slotted disc 249 is of the corrugated type in this example.
  • the slots do not extend all the way through the disc 249 but form pits or grooves.
  • the bottoms of the pits or grooves may be differently reflective to the surface of the disc that is closest to the sensor.
  • movement of the disc 249 can be detected in substantially the same was as described above with reference to Figure 7e .
  • the surface of first portion 23 that is opposite to sensor 51 may be designed to be differently reflective in an alternating pattern.
  • the Figure 10 data collection device is absent of a display, although a display for displaying a delivered dose may instead be provided.
  • FIG 11 is a block diagram of the data collection device 20, 120, 140, 220, 240.
  • the data collection device 20 includes a processor arrangement 50 including one or more processors, such as a microprocessor, a Digital Signal Processor (DSP), Application Specific Integrated Circuit (ASIC), Field Programmable Gate Array (FPGA) or the like, together with memory units 52a, 52b, including program memory 52a and main memory 52b, which can store software for execution by the processor arrangement 50 and data generated during use of the data collection device such as counted pulses, derived dose size, time stamp, etc.
  • the switch 53 connects the power source 54 to the electronic components of the device, including the sensor arrangement 51, when operated.
  • the display 22a may or may not be present.
  • the first and second electrical contacts 30, 31 may provide a data connection between the processor arrangement 50 and display 22a when engaged.
  • a sensor arrangement 51 comprising one or more sensors, is provided for detecting rotational movement between the first portion 23 and the second portion 24.
  • the resolution of the sensing arrangement 51 is determined by the design of the injection device 1.
  • a suitable resolution for the sensing arrangement 51 would be not more than 15°.
  • first magnets 56a are provided around a circumference of the inner surface of the first portion 23 and one or more second magnets 56b are provided around a circumference of the outer surface of the second portion 24, as shown in Figures 3 and 11 .
  • the sensor arrangement 51 is a transducer that varies its output due to variations in the magnetic field, based on the Hall effect, as the first portion 23 and first magnets 56a rotate relative to the second portion 24 and second magnets 56b.
  • the angle of rotation measured by the sensing arrangement 51 is proportional to the amount of medicament expelled. It is not necessary to determine a zero level or an absolute amount of medicament contained in the injection device 1. Moreover, since it is not necessary to monitor the numbers or tick marks on the number sleeve 70 displayed through the dosage window 13, the data collection device 20 may be designed so that it does not obscure the dosage window 13.
  • the medicament amount delivered is determined by the data collection device 20 independent from the dosage that is programmed into the injection device 1. Determining the delivered medicament amount provides a direct and thus more reliable information about the amount of medicament that is injected compared to data collection devices that determine the amount of medicament that is set, thus being intended to be dispensed.
  • the sensor arrangement may include a microelectromechanical (MEMS) device or other magnetic sensor for detecting changes in a magnetic field.
  • MEMS microelectromechanical
  • an optical encoder including a light source, such as a light emitting diode (LED) and a light detector, such as an optical transducer, that monitors changes in light reflected from an inner surface of the first portion, where the inner surface first portion has one or regions of varying reflectivity around its circumference, such as tick marks or at least one shaped reflective region.
  • the sensing arrangement 51 may be a potentiometer.
  • a capacitive sensing arrangement may be used, where elements provided on the first portion 23 affect the capacitance between two plates in the sensing arrangement.
  • mechanical sensors with mechanical switches and/or tracks, may be used to detect the relative rotation between the first and second portions 23, 25.
  • An output 57 is provided, which may be a wireless communications interface for communicating with another device via a wireless network such as Wi-Fi or Bluetooth ® , or an interface for a wired communications link, such as a socket for receiving a Universal Series Bus (USB), mini-USB or micro-USB connector.
  • Figure 12 depicts an example of a system in which the data collection device 20 is connected to another device, such as a personal computer 60, via a wired connection 61 for data transfer.
  • the processor arrangement 50 may store determined delivered medicament amounts and time stamps for the injections as they are administered by the user and subsequently, transfer that stored data to the computer 60.
  • the computer 60 maintains a treatment log and/or forwards treatment history information to a remote location, for instance, for review by a medical professional.
  • the data collection device 20 is configured to store data such as delivered medicament amounts and time stamps of up to 35 injection events, According to a once-daily injection therapy this would be sufficient to store a treatment history of about one month.
  • Data storage is organized in a first-in first-out manner ensuring that most recent injection events are always present in the memory of the data collection device 20.
  • the injection event history in the data collection device 20 will be deleted.
  • the data remains in the data collection device 20 and the oldest data is deleted automatically once new data is stored. This way the log in the data collection device is built up over time during usage and will always comprise the most recent injection events.
  • other configuration could comprise a storage capacity of 70 (twice daily), 100 (three months) or any other suitable number of injection events depending on the therapy requirements and/or the preferences of the user.
  • the output 57 may be configured to transmit information using a wireless communications link and/or the processor arrangement 23 may be configured to transmit such information to the computer 40 periodically.
  • a power switch 58 is provided, together with a power source 59.
  • the power switch 58 may be provided by the first and second electrical contacts 30, 31, or the switch 53 where the power switch 58 responds to pressure applied to the second portion 24 by powering the data collection device 20 on or off, so that power may conserved when the injection device 1 is not being used.
  • the data collection device 20 is powered on again, the processor arrangement 50 may control the display 22a to show the determined medicament dose information 22a, to aid the memory of the user, and/or an elapsed time since the determined medicament dose was delivered.
  • the processor arrangement 23 may cause the display 22 to switch periodically between displaying the most recent determined medicament dosage information and the elapsed time.
  • the power source 54 may be a battery.
  • the endplate 22 may include a solar panel to recharge a rechargeable battery.
  • the power source may be a coin cell, or multiple coin cells arranged in series or parallel.
  • the power source 54 may be a piezo-electric generator, which generates power when the endplate 22 is pressed by the user, potentially avoiding the need for a battery.
  • a timer 55 is also provided.
  • the switch 53 or the first and second electrical contacts 30, 31 may be arranged to trigger the timer 55 when engaged and/or disengaged. For example, if the timer 55 is triggered on both engagement or disengagement of the first and second electrical contacts 30, 31,, or both operation and ceasing of operation of the switch 53, then the processor arrangement 50 may use the output from the timer to determine a length of time during which the injection button 11 was pressed, for example to determine the duration of an injection.
  • the processor arrangement 50 may use the timer 55 to monitor a length of time that has elapsed since an injection was completed, as indicated by a time of disengagement of the first and second electrical contacts 30, 31 or ceasing of operation of the switch 53.
  • the elapsed time may be shown on the display 22a, as depicted in Figure 2 .
  • the processor arrangement 50 may compare the elapsed time with a predetermined threshold, to determine whether a user may be attempting to administer another injection too soon after a previous injection and, if so, generate an alert such as an audible signal and/or a warning message on the display 22a.
  • the processor arrangement 50 may store information indicating that a dosage was delivered in that manner.
  • the elapsed time is compared with a predetermined threshold in the range of a few seconds, e.g. 10 seconds up to a few minutes, e.g. 5 minutes.
  • the predetermined threshold is set to 2 minutes. If the time elapsed since the last injection is two minutes or less, the processor arrangement 50 stores information indicating that the dosage was delivered as a "split dose".
  • Another optional purpose for monitoring the elapsed time by the processor arrangement 50 is to determine when the elapsed time has passed a predetermined threshold, suggesting that the user might have forgotten to administer another injection and, if so, generate an alert.
  • the data collection device 20 is used where the injection device 1 includes a component that can rotate as medicament is dispensed. However, in some injection devices, the dosage knob does not rotate during dose delivery. However, there might be another rotatable component close to the dose knob to which the first portion 23 can be attached directly or indirectly.
  • Figure 13 depicts an example of such an injection device 80. In Figure 13 , components similar to those of the injection device 1 shown in Figure 1 are indicated using the same reference labels. Also, the injection device 80 is shown with its cap 18 in place, covering the needle and medicament chamber.
  • the injection button and dosage knob are provided by a single component, knob 81.
  • a medicament dosage can be programmed into the injection device 72 by turning the knob 81, which rotates a sleeve 82 which extends outwards from a housing 83 of the injection device 70 as the programmed dosage increases.
  • turning the knob 81 also turns a number sleeve 70, so that a dosage amount is displayed in the dosage window 13.
  • the knob 81 When the knob 81 is pressed to administer an injection or prime shot, the knob 81 is partially decoupled from the sleeve 82, so they can rotate independently of one another. As medicament is expelled from the injection device 80, the sleeve 82 rotates and moves into the housing 83. Meanwhile, the knob 81 moves towards the housing but does not rotate.
  • Figure 14 is a block diagram of a data collection device 72 according to a further embodiment, which is capable of being used with the injection device 80 of Figure 13 that does not have a rotatable component to which the first portion can be directly attached. Components of the data collection device 72 that correspond to those of the data collection device 20 of Figure 2 are shown with the same reference labels.
  • the data collection device 72 is provided with a transfer arrangement 73.
  • the transfer arrangement 73 is configured so that, when the data collection device 72 is attached to the injection device, it engages a component of the injection device that rotates as medicament is expelled.
  • the transfer arrangement 73 responds to rotation of the rotatable component by causing the first portion 74 to rotate relative to the second portion 75.
  • the transfer arrangement 73 is mounted on the second portion 75 includes a friction wheel 76.
  • the friction wheel 76 has a substantially spherical, or ball, shape, so that the friction wheel 76 can pass over the knob 81 when the data collection device 72 is mounted to the injection device 80 and to allow for axial movement between the first portion 74 and second portion 75, for example when using a locking mechanism similar to that described with reference to the data collection device 20 and Figure 5 .
  • the friction wheel 76 may be attached to the second portion 75 by a resilient arm 77, to facilitate movement of the friction wheel 76 over the knob 81 when mounting or removing the data collection device 72.
  • Figure 14 depicts an embodiment in which the transfer arrangement 73 includes one friction wheel 76
  • other embodiments may include one or more additional friction wheels 76, such as two or three friction wheels. The provision of such additional friction wheels 76 may improve the reliability of transfer of rotation between the sleeve 82 and first portion 74.
  • the knob 81 of the injection device 80 is in contact with the second portion 75.
  • One or more resilient pads 45 may be provided between the second portion 75 and knob 81 to improve engagement therebetween.
  • One or more of formations, not shown, configured to co-operate with formations 71a, 71b, 71c on the knob 81 of the injection device 80, resilient pads 84 and resilient portions in the second portion 75 may be provided to enhance engagement between the second portion 75 and the knob 81, so that rotation of the second portion 75 causes rotation of the knob 81 and vice versa.
  • first portion 74 does not contact, or engage directly with, the knob 81. Therefore, the first portion 74 and second portion 75 may be locked together, as described above in relation to Figure 5 , so that the injection device 80 can be programmed by turning the first portion 74, to rotate the second portion 75 and, therefore, the knob 81.
  • the user may press the second portion 75, which in turn depresses the knob 81, to dispense the programmed amount of medicament from the injection device 80.
  • the axial movement of the second portion 75 relative to the first portion 74 releases the locking mechanism that prevents rotation of the first portion 74 relative to the second portion 75.
  • the knob 81 moves towards the housing 83 but does not rotate.
  • the sleeve 82 rotates while it moves back into the housing 83.
  • the rotation of the sleeve 82 is transferred to the first portion 74 through the transfer arrangement 73. Therefore, the first portion 74 is caused to rotate relative to the second portion 75.
  • the sensor arrangement 51 detects the angle of rotation from which the medicament dosage amount can be determined, as described above in relation to the data collection device 20 of Figure 2 .
  • the switch 53 in the Figure 2 embodiment is formed of electrical contacts, and in the first to fourth variations of a switch.
  • the switch may for instance be a lever switch, a dome switch, a slider switch, a rubber keypad switch. It may be a capacitive touch switch or a resistive touch switch. It may be a tactile micro switch.
  • the switch 53 may be generally referred to as a microswitch.
  • the first portion 23 may facilitate gripping by the user through radial features, as shown in Figure 9 , or a rubberized component, as shown in Figures 10 .
  • the peripheral surface of the first portion 23 may be roughened, or provided with an adhesive or tactile coating, be made of or coated with a high friction material, or have some other gripable features.
  • a spring element is coupled to a center of the distal end of the capsule 242 at a center, proximal portion and is coupled to the first portion 23 at a distal, peripheral portion.
  • a feature, for instance a depression, is provided on the capsule 244 to receive the center part of the spring element.
  • the spring element may not contact the dose button 11.
  • the spring element compresses and communicates the force to the dose button 11.
  • This arrangement can provide a low-friction rotation center for rotation of the first portion 23 relative to the second portion 24, along with guidance for the location of the capsule 244. It can also provide good axial tolerance compensation.
  • a spring that does not compress significantly upon application of a force that is sufficient to operate the switch 53 this can provide good serial activation of the switch prior to activation of the dose delivery mechanism of the injection device 1.
  • embodiments of the invention may be used for other purposes, such as monitoring of injections of other medicaments.
  • the injection device 1 is configured to inject or infuse a medicament into a patient.
  • delivery could be sub-cutaneous, intra-muscular, or intravenous. Delivery could be needleless.
  • the injection device 1 could be operated by a patient or care-giver, such as a nurse or physician, and may be one of various types of safety syringe, pen-injector, or auto-injector.
  • the injection device 1 can include a cartridge-based system that requires piercing a sealed ampule before use. Volumes of medicament delivered with these various devices can range from about 0.5 ml to about 2 ml.
  • the injection device 1 may be a large volume device ("LVD") or patch pump, configured to adhere to a patient's skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a "large" volume of medicament (typically about 2 ml to about 10 ml).
  • the injection device 1 may also be customized in order to operate within required specifications.
  • the injection device 1 may be customized to inject a medicament within a certain time period (e.g., about 3 to about 20 seconds for auto-injectors, and about 10 minutes to about 60 minutes for an LVD).
  • the injection device 1 may include a hollow needle ranging from about 25 to about 31 Gauge in size. Common sizes are 27 and 29 Gauge.
  • the injection device 1 can also include one or more automated functions. For example, one or more of needle insertion, medicament injection, and needle retraction can be automated. Energy for one or more automation steps can be provided by one or more energy sources. Energy sources can include, for example, mechanical, pneumatic, chemical, or electrical energy. For example, mechanical energy sources can include springs, levers, elastomers, or other mechanical mechanisms to store or release energy. One or more energy sources can be combined into a single device. Devices can further include gears, valves, or other mechanisms to convert energy into movement of one or more components of a device.
  • the one or more automated functions of such an injection device 1 may each be activated via an activation mechanism.
  • an activation mechanism can include one or more of a button, a lever, a needle sleeve, or other activation component.
  • Activation of an automated function may be a one-step or multi-step process. That is, a user may need to activate one or more activation components in order to cause the automated function. For example, in a one-step process, a user may depress a needle sleeve against their body in order to allow injection of a medicament to be provided.
  • the injection device 1 may require a multi-step activation of an automated function. For example, a user may be required to depress a button and retract a needle shield in order to cause injection.
  • activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence.
  • activation of a first automated function may activate at least two of needle insertion, medicament injection, and needle retraction.
  • the injection device 1 may also require a specific sequence of steps to cause the one or more automated functions to occur.
  • the injection device 1 may operate with a sequence of independent steps.
  • the injection device 1 can include one or more functions of a safety syringe, pen-injector, or auto-injector.
  • the injection device 1 may include a mechanical energy source configured to automatically inject a medicament (as typically found in an auto-injector) and a dose setting mechanism (as typically found in a pen-injector).
  • the injection device 1 may be disposable or it may be reusable.
  • the injection device 1 may provide a fixed dose or a user-settable dose.
  • the drug or medicament may be contained in a primary package or "drug container" adapted for use with a drug delivery device.
  • the drug container may be, e.g., a cartridge, syringe, reservoir, or other vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more pharmaceutically active compounds.
  • the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years.
  • the drug container may be or may include a dual-chamber cartridge configured to store two or more components of a drug formulation (e.g., a drug and a diluent, or two different types of drugs) separately, one in each chamber.
  • the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components of the drug or medicament prior to and/or during dispensing into the human or animal body.
  • the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing.
  • the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
  • the drug delivery devices and drugs described herein can be used for the treatment and/or prophylaxis of many different types of disorders.
  • exemplary disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism.
  • Further exemplary disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.
  • ACS acute coronary syndrome
  • angina myocardial infarction
  • cancer macular degeneration
  • inflammation hay fever
  • atherosclerosis and/or rheumatoid arthritis.
  • Exemplary drugs for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof.
  • the term "derivative” refers to any substance which is sufficiently structurally similar to the original substance so as to have substantially similar functionality or activity (e.g., therapeutic effectiveness).
  • Exemplary insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • Exemplary insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-
  • GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example: Lixisenatide / AVE0010 / ZP10 / Lyxumia, Exenatide / Exendin-4 / Byetta / Bydureon / ITCA 650 / AC-2993 (a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide / Victoza, Semaglutide, Taspoglutide, Syncria / Albiglutide, Dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701
  • An exemplary oligonucleotide is, for example: mipomersen / Kynamro, a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.
  • DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
  • hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
  • Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Nafarelin
  • Goserelin Goserelin.
  • Exemplary polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • An example of a hyaluronic acid derivative is Hylan G-F 20 / Synvisc, a sodium hyaluronate.
  • antibody refers to an immunoglobulin molecule or an antigen-binding portion thereof.
  • antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments, which retain the ability to bind antigen.
  • the antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody.
  • the antibody has effector function and can fix complement.
  • the antibody has reduced or no ability to bind an Fc receptor.
  • the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
  • fragment refers to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen.
  • Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments.
  • Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
  • CDR complementarity-determining region
  • framework region refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding.
  • framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
  • Exemplary antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).
  • anti PCSK-9 mAb e.g., Alirocumab
  • anti IL-6 mAb e.g., Sarilumab
  • anti IL-4 mAb e.g., Dupilumab
  • the compounds described herein may be used in pharmaceutical formulations comprising (a) the compound(s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier.
  • the compounds may also be used in pharmaceutical formulations that include one or more other active pharmaceutical ingredients or in pharmaceutical formulations in which the present compound or a pharmaceutically acceptable salt thereof is the only active ingredient.
  • the pharmaceutical formulations of the present disclosure encompass any formulation made by admixing a compound described herein and a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable salts of any drug described herein are also contemplated for use in drug delivery devices.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • Acid addition salts are e.g. HCl or HBr salts.
  • Basic salts are e.g. salts having a cation selected from an alkali or alkaline earth metal, e.g.
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
  • solvates are for example hydrates or alkanolates such as methanolates or ethanolates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (15)

  1. Dispositif de collecte de données (20) pour la fixation à un dispositif d'injection (1), le dispositif d'injection (1) comprenant un bouton de dose (11) agencé pour causer, lorsqu'il est pressé, l'expulsion d'un médicament depuis le dispositif d'injection (1) ;
    le dispositif de collecte de données (20) comprenant :
    une première partie (23) comprenant un manchon conçu pour fixer le dispositif de collecte de données au dispositif d'injection (1) en entrant en prise avec une molette de dosage (12) du dispositif d'injection ;
    une seconde partie (24) fixée de manière rotative à la première partie, la seconde partie étant conçue pour entrer en prise avec le bouton de dose (11) du dispositif d'injection, la seconde partie (24) étant agencée pour presser sur le bouton de dose (11) lorsqu'une pression est appliquée sur la seconde partie (24) ;
    un agencement de capteur (51) configuré pour détecter une rotation de la première partie par rapport à la seconde partie pendant l'expulsion du médicament par le dispositif d'injection ; et
    un agencement de processeur (50) configuré pour, sur la base dudit mouvement détecté, déterminer une quantité de médicament expulsée par le dispositif d'injection.
  2. Dispositif de collecte de données selon la revendication 1, dans lequel :
    la seconde partie comprend une partie externe (26) possédant des premiers contacts électriques (30) ;
    la seconde partie comprend une partie interne (27) possédant des seconds contacts électriques (31) ; et
    la partie interne est mobile axialement par rapport à la partie externe pour mettre en prise lesdits premiers contacts électriques avec lesdits seconds contacts électriques lorsqu'une pression est appliquée à la partie externe.
  3. Dispositif de collecte de données selon la revendication 2, comprenant un générateur piézoélectrique conçu pour alimenter le dispositif de collecte de données lorsqu'une pression est appliquée à la partie externe (26).
  4. Dispositif de collecte de données selon la revendication 2 ou 3, comprenant un minuteur (55) déclenché lorsque lesdits premiers contacts électriques (30) sont en prise avec les seconds contacts électriques (31) et/ou libérés de ceux-ci, dans lequel le dispositif de collecte de données est configuré pour déterminer un temps écoulé depuis le dernier déclenchement du minuteur et pour générer une alerte si le temps écoulé est incohérent avec une condition de seuil.
  5. Dispositif de collecte de données selon la revendication 4, dans lequel l'agencement de processeur (50) est configuré pour déterminer une estampille temporelle pour l'administration du dosage de médicament à l'aide dudit minuteur (55) et pour mémoriser le dosage de médicament déterminé et ladite estampille temporelle, et dans lequel l'agencement de processeur est configuré pour transmettre un journal de dosages de médicament déterminés et des informations d'estampille temporelle à un autre dispositif.
  6. Dispositif de collecte de données selon l'une quelconque des revendications précédentes, configuré pour commuter entre une première configuration dans laquelle une rotation de la première partie (23) par rapport à la seconde partie (24) est évitée et une seconde configuration dans laquelle la première partie peut être tournée par rapport à la seconde partie.
  7. Dispositif de collecte de données selon l'une quelconque des revendications précédentes, comprenant :
    un agencement de transfert (73) conçu pour entrer en prise avec la molette de dosage (12) du dispositif d'injection (1) ;
    dans lequel l'agencement de transfert est conçu pour tourner la première partie (23) par rapport à la seconde partie (24) lorsque la molette de dosage tourne.
  8. Dispositif de collecte de données selon la revendication 7, dans lequel ledit agencement de transfert (73) comprend une roue à friction (76).
  9. Dispositif de collecte de données selon l'une quelconque des revendications précédentes, dans lequel la première partie (23) possède une surface interne faite d'un matériau déformable.
  10. Dispositif de collecte de données selon l'une quelconque des revendications précédentes, dans lequel la première partie (23) possède une surface interne conçue pour s'accoupler avec des éléments externes de la molette de dosage (12) du dispositif d'injection.
  11. Dispositif de collecte de données selon la revendication 10, dans lequel la surface interne de la première partie (23) comprend des rainures qui correspondent par la forme à des formations sur la surface de la molette de dosage (12) du dispositif d'injection.
  12. Dispositif de collecte de données selon la revendication 11, dans lequel les rainures possèdent des embouchures au niveau d'une extrémité ouverte de la première partie (23) et dans lequel les rainures s'effilent vers une largeur plus étroite à distance de l'extrémité ouverte de la première partie.
  13. Dispositif de collecte de données selon l'une quelconque des revendications précédentes, dans lequel la première partie (23) est dotée d'une ou de plusieurs éléments de préhension externes (123) pour faciliter la préhension de la première partie par un utilisateur pour effectuer une rotation du dispositif de collecte de données (20) par rapport à un boîtier (10) du dispositif d'injection (1).
  14. Dispositif de collecte de données selon l'une quelconque des revendications précédentes, dans lequel l'agencement de capteur (51) comprend un capteur optique et/ou un capteur magnétique et/ou un capteur capacitif et/ou un capteur mécanique.
  15. Appareil d'administration de médicament comprenant :
    un dispositif d'injection (1) comprenant une molette de dosage (12) conçue pour tourner à mesure qu'un médicament est expulsé du dispositif d'injection et un bouton de dose (11) conçu pour provoquer une expulsion du médicament depuis le dispositif d'injection ; et
    un dispositif de collecte de données (20) selon l'une quelconque des revendications 1 à 14.
EP16729241.6A 2015-06-09 2016-06-09 Dispositif de collecte de donnees destine a etre fixe a un dispositif d'injection Active EP3307357B2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP19209180.9A EP3656423B1 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de données pour fixation sur un dispositif d'injection
EP23208919.3A EP4316552A3 (fr) 2015-06-09 2016-06-09 Appareil de collecte de données destiné à être fixé à un dispositif d'injection
PL16729241.6T PL3307357T5 (pl) 2015-06-09 2016-06-09 Urządzenie do gromadzenia danych do zamocowania na urządzeniu wstrzykującym

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171252.8A EP3103492A1 (fr) 2015-06-09 2015-06-09 Dispositif de collecte de donnees destine a etre fixe a un dispositif d'injection
EP15199308 2015-12-10
PCT/EP2016/063139 WO2016198516A1 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de données pour fixation sur un dispositif d'injection

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP23208919.3A Division EP4316552A3 (fr) 2015-06-09 2016-06-09 Appareil de collecte de données destiné à être fixé à un dispositif d'injection
EP19209180.9A Division EP3656423B1 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de données pour fixation sur un dispositif d'injection
EP19209180.9A Division-Into EP3656423B1 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de données pour fixation sur un dispositif d'injection

Publications (3)

Publication Number Publication Date
EP3307357A1 EP3307357A1 (fr) 2018-04-18
EP3307357B1 EP3307357B1 (fr) 2020-05-06
EP3307357B2 true EP3307357B2 (fr) 2023-06-07

Family

ID=56131518

Family Applications (3)

Application Number Title Priority Date Filing Date
EP23208919.3A Pending EP4316552A3 (fr) 2015-06-09 2016-06-09 Appareil de collecte de données destiné à être fixé à un dispositif d'injection
EP16729241.6A Active EP3307357B2 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de donnees destine a etre fixe a un dispositif d'injection
EP19209180.9A Active EP3656423B1 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de données pour fixation sur un dispositif d'injection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP23208919.3A Pending EP4316552A3 (fr) 2015-06-09 2016-06-09 Appareil de collecte de données destiné à être fixé à un dispositif d'injection

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19209180.9A Active EP3656423B1 (fr) 2015-06-09 2016-06-09 Dispositif de collecte de données pour fixation sur un dispositif d'injection

Country Status (10)

Country Link
US (7) US10874802B2 (fr)
EP (3) EP4316552A3 (fr)
JP (2) JP6901975B2 (fr)
CN (3) CN112206381B (fr)
DK (1) DK3307357T4 (fr)
ES (1) ES2805230T5 (fr)
HK (1) HK1248622A1 (fr)
HU (1) HUE050055T2 (fr)
PL (1) PL3307357T5 (fr)
WO (1) WO2016198516A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6616073B2 (ja) 2011-03-24 2019-12-04 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 医療デバイスで実行可能な作動動作を検出するためのデバイス及び方法
CA3009221A1 (fr) 2014-12-23 2016-06-30 Automed Pty Ltd Appareil d'administration, systeme et procedes associes
EP3058970A1 (fr) 2015-02-19 2016-08-24 Sanofi-Aventis Deutschland GmbH Dispositif de collecte de données destiné à être fixé à un dispositif d'injection
EP4316552A3 (fr) 2015-06-09 2024-04-17 Sanofi-Aventis Deutschland GmbH Appareil de collecte de données destiné à être fixé à un dispositif d'injection
US10864327B2 (en) 2016-01-29 2020-12-15 Companion Medical, Inc. Automatic medication delivery tracking
US10892525B2 (en) * 2016-06-29 2021-01-12 University Of Kentucky Research Foundation Rechargeable batteries including high-voltage cathode and redox shuttle conferring overcharge protection
CN113694314B (zh) 2016-07-15 2023-09-05 伊莱利利公司 用于药物输送装置的剂量检测模块
JP7036803B2 (ja) 2016-09-09 2022-03-15 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 注射デバイスに取り付けるためのデータ収集装置
RU2754301C2 (ru) 2016-12-07 2021-08-31 Санофи Устройство для сбора данных, прикрепляемое к инъекционному устройству
MA47679A (fr) 2017-02-28 2020-01-08 Lilly Co Eli Détection de dose et identification de médicament pour dispositif d'administration de médicament
KR20190005572A (ko) * 2017-07-07 2019-01-16 최규동 펜형 주사장치의 범용 장착형 투입량 측정 및 관리 시스템
US20190022330A1 (en) * 2017-07-21 2019-01-24 Verily Life Sciences Llc Strain based dosage measurement
AU2018318219B2 (en) * 2017-08-18 2021-07-15 Eli Lilly And Company Dosage measurement module on injection pen
US11471608B2 (en) * 2017-08-21 2022-10-18 Eli Lilly And Company Medication delivery device with sensing system
ES2927561T3 (es) * 2017-09-22 2022-11-08 Novo Nordisk As Dispositivo accesorio para dispositivo de administración de fármacos
CN111194229B (zh) * 2017-10-06 2023-09-15 赛诺菲 数据收集装置
JP7203098B2 (ja) * 2017-10-19 2023-01-12 サノフイ 薬剤投与デバイスおよびデータ収集デバイス
AU2018372009A1 (en) * 2017-11-23 2020-07-09 Sanofi Medicament injection device with rotary encoder
EP3495008A1 (fr) * 2017-12-06 2019-06-12 Sanofi Servo-actionneur d'enroulement et dispositif d'administration de médicaments
US11116899B2 (en) 2017-12-12 2021-09-14 Bigfoot Biomedical, Inc. User interface for diabetes management systems and devices
US11077243B2 (en) 2017-12-12 2021-08-03 Bigfoot Biomedical, Inc. Devices, systems, and methods for estimating active medication from injections
US11083852B2 (en) 2017-12-12 2021-08-10 Bigfoot Biomedical, Inc. Insulin injection assistance systems, methods, and devices
US10987464B2 (en) 2017-12-12 2021-04-27 Bigfoot Biomedical, Inc. Pen cap for insulin injection pens and associated methods and systems
US11464459B2 (en) 2017-12-12 2022-10-11 Bigfoot Biomedical, Inc. User interface for diabetes management systems including flash glucose monitor
US11383043B2 (en) 2017-12-12 2022-07-12 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
CN111712282B (zh) * 2017-12-20 2023-03-03 赛诺菲 用于附接到注射装置的装置
JP2021508555A (ja) * 2017-12-28 2021-03-11 サノフイＳａｎｏｆｉ 注射デバイスに取り付けるためのデータ収集装置
EP3517153A1 (fr) * 2018-01-24 2019-07-31 Insulcloud, S.L. Dispositif de surveillance avec adaptateur universel pour stylos d'injection de médicaments
WO2019162235A1 (fr) 2018-02-20 2019-08-29 Novo Nordisk A/S Dispositif additionnel avec élément de montage pour mise en prise avec un élément de type cadran
CN111867660B (zh) 2018-02-22 2022-06-10 伊莱利利公司 用于药物递送装置的剂量检测***模块
WO2019186261A1 (fr) * 2018-03-26 2019-10-03 Patients Pending Ltd. Dispositifs de capuchon, systèmes, et procédés destinés à des dispositifs de distribution de liquide
CN109157714A (zh) * 2018-04-24 2019-01-08 无锡市人民医院 一种自动报数的有声胰岛素笔
US11185636B2 (en) 2018-07-26 2021-11-30 Verily Life Sciences Llc Electrostatic rotary encoder
WO2020035406A1 (fr) * 2018-08-15 2020-02-20 Sanofi Appareil de collecte de données destiné à être fixé sur un dispositif d'injection
USD903857S1 (en) 2018-08-29 2020-12-01 Eli Lilly And Company Component for a drug delivery device
USD914199S1 (en) 2018-08-29 2021-03-23 Eli Lilly And Company Component for a drug delivery device
USD903858S1 (en) 2018-08-29 2020-12-01 Eli Lilly And Company Drug delivery device
USD903105S1 (en) 2018-08-29 2020-11-24 Eli Lilly And Company Component for a drug delivery device
US11229749B2 (en) * 2018-09-06 2022-01-25 Verily Life Sciences Llc Plate capacitor for dosage sensing
WO2020055599A1 (fr) * 2018-09-12 2020-03-19 Becton, Dickinson And Company Dispositif de raccord universel pour injecteurs de stylo
WO2020104285A1 (fr) * 2018-11-23 2020-05-28 Sanofi Dispositif supplémentaire pour un dispositif d'injection
JP7474764B2 (ja) * 2018-12-04 2024-04-25 ノボ・ノルデイスク・エー／エス 移動センサシステムを有する薬剤送達アセンブリ
EA202091758A1 (ru) * 2018-12-14 2020-10-23 Эли Лилли Энд Компани Устройство доставки лекарственного препарата с измеряемым элементом
KR102194269B1 (ko) * 2018-12-31 2020-12-22 권기만 투여량 측정 및 관리가 가능한 펜형 주사장치의 휴대용 냉장 보관 케이스 시스템
US11948671B2 (en) 2019-04-11 2024-04-02 Medtronic Minimed, Inc. Intelligent accessories for medicine dispensing device
BR112021021021A2 (pt) * 2019-04-26 2021-12-14 Biocorp Production SA Módulo de monitoramento de injeção e processo para calcular uma quantidade real de medicamento ejetada ou injetada a partir de um sistema de injeção de caneta
WO2020249776A1 (fr) * 2019-06-13 2020-12-17 Sanofi Appareil de détection d'une dose de médicament administrée depuis un dispositif d'injection
CN110624160B (zh) * 2019-10-21 2020-11-13 北京糖护科技有限公司 数字化高精度胰岛素笔注射数据采集装置
PL431693A1 (pl) * 2019-10-31 2021-05-04 Copernicus Spółka Z Ograniczoną Odpowiedzialnością Urządzenie do podawania leku z układem do pomiaru dawki ustawionej lub dawki podanej
JP2023502025A (ja) * 2019-11-14 2023-01-20 サノフイ 薬物送達デバイスの無線データ通信アクセサリ
WO2021116052A1 (fr) * 2019-12-09 2021-06-17 Sanofi Dispositif d'administration de médicament
TWI777138B (zh) * 2020-03-02 2022-09-11 廣達電腦股份有限公司 胰島素劑量偵測裝置
US11957542B2 (en) 2020-04-30 2024-04-16 Automed Patent Holdco, Llc Sensing complete injection for animal injection device
AU2020455394A1 (en) * 2020-06-23 2023-02-02 Biocorp Production S.A. Injection monitoring module
KR102284455B1 (ko) * 2021-02-18 2021-08-02 주식회사 바로메디 약물 주입기 관리용 시스템
EP4395860A1 (fr) * 2021-08-09 2024-07-10 Create to Overcome LLC Doseur acoustique
CN116672544A (zh) * 2022-02-22 2023-09-01 上海微创生命科技有限公司 注射量采集装置及胰岛素注射***

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008399B2 (en) † 2001-02-14 2006-03-07 Novo Nordisk A/S Electronically controlled device
US20140194826A1 (en) † 2011-07-07 2014-07-10 Novo Nordisk A/S Drug delivery injection pen with add-on dose capturing and display module
WO2014128156A1 (fr) † 2013-02-19 2014-08-28 Novo Nordisk A/S Module capteur rotatif à commutateur axial

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533575A (en) 1895-02-05 wilkens
CH675078A5 (fr) 1988-01-22 1990-08-31 Nosta Ag
US4959056A (en) 1988-06-14 1990-09-25 Wayne State University Digital dispenser
DK68789A (da) 1989-02-14 1990-08-15 Novo Nordisk As Injektionspen
SE466684B (sv) 1989-03-07 1992-03-23 Draco Ab Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
GB9007113D0 (en) 1990-03-29 1990-05-30 Sams Bernard Dispensing device
EP0525525B1 (fr) 1991-07-24 1995-05-03 Medico Development Investment Company Injecteur
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
US5279586A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Reusable medication delivery pen
CH682805A5 (de) 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
ZA941881B (en) 1993-04-02 1995-09-18 Lilly Co Eli Manifold medication injection apparatus and method
CA2129284C (fr) 1993-11-24 1999-03-09 Kenneth J. Niehoff Regulation de l'entrainement du plongeur pour l'injection de liquides a des animaux
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
WO1996027400A1 (fr) 1995-03-07 1996-09-12 Eli Lilly And Company Distributeur recyclable de medicament
US6246322B1 (en) 1995-12-26 2001-06-12 Headwaters Research & Development, Inc. Impulse characteristic responsive missing object locator operable in noisy environments
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
ES2200155T3 (es) 1996-02-23 2004-03-01 Novo Nordisk A/S Jeringuilla con una representacion electronica de los parametros.
AU7331598A (en) 1997-07-11 1999-02-08 Novo Nordisk A/S An apparatus for the registration of the setting of a medical device
DE19730999C1 (de) 1997-07-18 1998-12-10 Disetronic Licensing Ag Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts
US5921966A (en) 1997-08-11 1999-07-13 Becton Dickinson And Company Medication delivery pen having an improved clutch assembly
CH692543A5 (de) 1997-09-25 2002-07-31 Disetronic Licensing Ag Abgabevorrichtung mit Signalgeber.
DK1003581T3 (da) 1998-01-30 2000-12-18 Novo Nordisk As Injektionssprøjte
US5961495A (en) 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
JPH11267207A (ja) 1998-03-24 1999-10-05 Miyota Kk 携帯型注射器
US7193521B2 (en) 1998-10-29 2007-03-20 Medtronic Minimed, Inc. Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump
DE29904864U1 (de) 1999-03-17 2000-08-03 B. Braun Melsungen Ag, 34212 Melsungen Injektionsvorrichtung mit einem Pen
WO2001010484A1 (fr) 1999-08-05 2001-02-15 Becton, Dickinson And Company Stylo d'administration de produits medicaux
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
US6585698B1 (en) 1999-11-01 2003-07-01 Becton, Dickinson & Company Electronic medical delivery pen having a multifunction actuator
GB0007071D0 (en) 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
US6500169B1 (en) 2000-05-15 2002-12-31 Stryker Corporation Powered surgical handpiece with membrane switch
WO2001091098A1 (fr) 2000-05-24 2001-11-29 Hitachi, Ltd. Terminal portable et afficheur commutable entre couleur et noir-et-blanc
JP2001357132A (ja) 2000-06-12 2001-12-26 Iwami Kaihatsu Kk 医薬品の投与システム及び投与方法
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
IL156245A0 (en) 2000-12-22 2004-01-04 Dca Design Int Ltd Drive mechanism for an injection device
US6899699B2 (en) 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
US7044933B2 (en) 2001-03-01 2006-05-16 Scimed Life Systems, Inc. Fluid injection system for coronary intervention
US6817986B2 (en) 2001-04-13 2004-11-16 Avant Medical Corp. Jet injector with data logging system for use in compliance and dose monitoring programs
US20050192530A1 (en) 2001-04-13 2005-09-01 Penjet Corporation Method and apparatus for needle-less injection with a degassed fluid
PT1392377E (pt) 2001-05-16 2007-05-31 Lilly Co Eli Aparelho injector de medicação com unidade de accionamento que facilita o reposicionamento
US20030208113A1 (en) 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6793660B2 (en) 2001-08-20 2004-09-21 Synthes (U.S.A.) Threaded syringe for delivery of a bone substitute material
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
DE10326706A1 (de) 2003-06-04 2005-01-05 Schott Ag Spritze, insbesondere für medizinische Anwendungen, sowie Verfahren zum Herstellen einer solchen
DE10327261B4 (de) 2003-06-17 2006-03-02 Disetronic Licensing Ag Infusionspumpe und Verfahren zur Überprüfung einer Infusionspumpe
US20050080384A1 (en) 2003-10-10 2005-04-14 Green Henry Edward Illuminating syringe
DE10350422A1 (de) 2003-10-29 2005-06-16 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Verfahren zur Identifizierung und/oder Prüfung und/oder Freigabe von insbesondere vorgefüllten medizinischen Spritzen vor ihrer Anwendung sowie Testvorrichtung zur Durchführung des Verfahrens
US7771389B2 (en) 2004-02-17 2010-08-10 Mallinckrodt Inc. Injector auto purge
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
ATE406850T1 (de) 2004-06-17 2008-09-15 Cadent Ltd Verfahren und gerät zur farbbildformung einer dreidimensionalen struktur
DE602005018518D1 (de) 2004-10-21 2010-02-04 Novo Nordisk As Injektionsvorrichtung mit einem prozessor zur sammlung von ausstossinformationen
DE102004063664A1 (de) 2004-12-31 2006-07-20 Tecpharma Licensing Ag Echtzeitanzeige für eine Vorrichtung zur dosierten Verabreichung eines Produkts
DE102004063647A1 (de) 2004-12-31 2006-07-20 Tecpharma Licensing Ag Vorrichtung zur dosierten Verabreichung eines fluiden Produkts mit Kupplung
DE102004063650B4 (de) 2004-12-31 2022-10-20 Ypsomed Ag Lebensdaueranzeige für eine Vorrichtung zur dosierten Verabreichung eines Produkts
US8231573B2 (en) 2005-02-01 2012-07-31 Intelliject, Inc. Medicament delivery device having an electronic circuit system
DE602006019712D1 (fr) 2005-05-10 2011-03-03 Novo Nordisk As
US20090043253A1 (en) 2005-10-11 2009-02-12 Blake Podaima Smart medical compliance method and system
US20070265579A1 (en) 2006-05-10 2007-11-15 Gennady Kleyman Dental syringe
US7996050B2 (en) 2006-02-28 2011-08-09 Lg Electronics Inc. Input device for an electronic device and electronic device having the same
RU2459247C2 (ru) 2006-03-20 2012-08-20 Ново Нордиск А/С Электронный модуль для механического устройства введения лекарственных средств
US8994382B2 (en) 2006-04-12 2015-03-31 Novo Nordisk A/S Absolute position determination of movably mounted member in medication delivery device
ES2411732T3 (es) 2006-09-29 2013-07-08 Novo Nordisk A/S Dispositivo de inyección con medios de detección electrónicos
WO2008091838A2 (fr) 2007-01-22 2008-07-31 Intelliject, Inc. Injecteur médical équipé d'un système de détection et de surveillance de l'observance
US8267921B2 (en) 2007-07-20 2012-09-18 Medingo Ltd. Manually operable portable infusion device
EP2060284A1 (fr) 2007-11-13 2009-05-20 F.Hoffmann-La Roche Ag Dispositif d'injection médical avec moyen d'entrée de données et écran pivotant
CN101909673B (zh) 2007-12-31 2012-12-26 诺沃-诺迪斯克有限公司 电子监控的注射设备
US9550031B2 (en) 2008-02-01 2017-01-24 Reciprocal Labs Corporation Device and method to monitor, track, map, and analyze usage of metered-dose inhalers in real-time
US8647309B2 (en) 2008-05-02 2014-02-11 Sanofi-Aventis Deutschland Gmbh Medication delivery device
RU2508922C2 (ru) 2008-08-29 2014-03-10 Ново Нордиск А/С Медицинское инъекционное устройство с индикатором временной задержки
US9089650B2 (en) 2008-10-01 2015-07-28 Novo Nordisk A/S Medical assembly with monitoring device
ES2713177T3 (es) * 2008-10-28 2019-05-20 Hoffmann La Roche Un procedimiento para supervisar la operación de un dispositivo de administración de medicamentos, un módulo electrónico y un sistema de administración de medicamentos
US8613719B2 (en) 2008-11-03 2013-12-24 Calibra Medical, Inc. Dosage sensing unit with tactile feedback
ES2673294T3 (es) 2008-11-06 2018-06-21 Novo Nordisk A/S Dispositivo de administración de fármacos asistido electrónicamente
CN102256642B (zh) 2008-12-16 2014-09-17 松下健康医疗器械株式会社 药剂投予装置
JP5711155B2 (ja) 2009-02-27 2015-04-30 ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． 薬物送達ペンのための医療モジュール
US20100286612A1 (en) 2009-05-06 2010-11-11 William Cirillo Medication injection supervisor device
US9950116B2 (en) 2009-06-01 2018-04-24 Sanofi-Aventis Deutschland Gmbh Dose setting mechanism for priming a drug delivery device
US20130123685A1 (en) 2009-06-03 2013-05-16 Novo Nordisk A/S Electronically monitored injection device
US8394053B2 (en) 2009-11-06 2013-03-12 Crisi Medical Systems, Inc. Medication injection site and data collection system
US8945066B2 (en) 2009-11-06 2015-02-03 Crisi Medical Systems, Inc. Medication injection site and data collection system
TWI633902B (zh) 2010-03-22 2018-09-01 賽諾菲阿凡提斯德意志有限公司 用於判定與醫療裝置有關的資訊之裝置、方法、系統及電腦程式
KR101939267B1 (ko) 2010-07-21 2019-01-16 삼성전자주식회사 주사기의 주사량 측정 장치 및 방법
WO2012046199A1 (fr) 2010-10-05 2012-04-12 Hendrik Meiring Surveillance de dosage de liquide
US8520209B2 (en) 2010-10-14 2013-08-27 Hewlett-Packard Development Company, L.P. Article, system, and method for color measurement
JP2012135594A (ja) * 2010-12-25 2012-07-19 Toshikatsu Hino 記憶型インスリン注入器
WO2012118687A1 (fr) 2011-02-28 2012-09-07 Merck Sharp & Dohme Corp. Injecteur actionné manuellement avec séquence d'injection limitée
JP6616073B2 (ja) * 2011-03-24 2019-12-04 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 医療デバイスで実行可能な作動動作を検出するためのデバイス及び方法
TWI600446B (zh) * 2011-03-25 2017-10-01 賽諾菲阿凡提斯德意志有限公司 藥劑設定機構及注射裝置
CN103458945B (zh) * 2011-04-11 2016-01-13 诺沃—诺迪斯克有限公司 结合剂量监测的注射装置
WO2013004844A1 (fr) 2011-07-07 2013-01-10 Novo Nordisk A/S Stylo d'injection de médicament doté d'un module de capture et d'affichage de dose auxiliaire
US20140303560A1 (en) 2011-11-18 2014-10-09 Sanofi-Aventis Deutschland Gmbh Piston Driving Motor Arrangement
EP2814543B1 (fr) 2012-02-13 2017-10-25 Sanofi-Aventis Deutschland GmbH Injecteur de medicament du type stylo avec dispositif électronique supplémentaire de surveillance pour la surveillance du fonctionnement de l'injecteur
RU2018119916A (ru) * 2012-02-13 2018-11-14 Санофи-Авентис Дойчланд Гмбх Вспомогательное устройство для закрепления на инъекционном устройстве
EP2814544B1 (fr) * 2012-02-13 2016-07-06 Sanofi-Aventis Deutschland GmbH Dispositif supplementaire pour fixation sur un dispositif d'injection
CN104245020B (zh) * 2012-02-13 2018-04-03 赛诺菲-安万特德国有限公司 笔式注射装置及其电子夹式模块
EP2839397A1 (fr) 2012-04-17 2015-02-25 Novo Nordisk A/S Dispositif d'administration de médicaments comprenant un élément d'identification de régime posologique
US8817258B2 (en) 2012-05-21 2014-08-26 Common Sensing Inc. Dose measurement system and method
EP2692378A1 (fr) * 2012-08-03 2014-02-05 Sanofi-Aventis Deutschland GmbH Injecteur de médicament du type stylo avec dispositif électronique supplémentaire de surveillance pour la surveillance du fonctionnement de l'injecteur
WO2014023763A1 (fr) 2012-08-10 2014-02-13 Sanofi-Aventis Deutschland Gmbh Dispositifs d'injection de médicament de type stylo et module de surveillance additionnel électronique pour surveiller et journaliser le réglage et l'administration de dose
WO2014037331A1 (fr) * 2012-09-06 2014-03-13 Sanofi-Aventis Deutschland Gmbh Dispositif d'injection de médicament du type stylo et module de surveillance d'ajout électronique pour surveiller et journaliser un réglage et une administration de dose
US20150290396A1 (en) * 2012-10-23 2015-10-15 Insuline Medical Ltd. Drug dispensing-tracking device, system and method
KR20140090763A (ko) 2013-01-10 2014-07-18 삼성전자주식회사 약물 주입기의 주사량 측정 장치
CN104918645B (zh) 2013-01-15 2018-10-12 赛诺菲-安万特德国有限公司 用于生成数字图像格式使用报告的医用注射附加装置
EP2762184A1 (fr) * 2013-02-05 2014-08-06 Sanofi-Aventis Deutschland GmbH Agencement d'entraînement pour dispositif de distribution de médicament
WO2014161955A1 (fr) 2013-04-05 2014-10-09 Novo Nordisk A/S Dispositif d'enregistrement adapté pour combiner des doses
CN105120927B (zh) 2013-04-22 2019-02-01 赛诺菲-安万特德国有限公司 用于收集与注射装置的使用有关的信息的辅助装置
WO2014173774A1 (fr) 2013-04-22 2014-10-30 Sanofi-Aventis Deutschland Gmbh Procédé d'assemblage d'un dispositif supplémentaire comprenant un module de caméra pour un stylo injecteur et ledit dispositif supplémentaire
DK2994180T3 (da) 2013-05-07 2019-12-09 Sanofi Aventis Deutschland Hjælpeanordning til fastgøring til en injektionsanordning
EP3736003A1 (fr) 2013-05-07 2020-11-11 Sanofi-Aventis Deutschland GmbH Dispositif d'injection
WO2015001008A1 (fr) 2013-07-05 2015-01-08 Sanofi-Aventis Deutschland Gmbh Appareil et procédé pour enregistrer la quantité de médicament éjectée d'un dispositif d'injection
EP3071260A1 (fr) 2013-11-21 2016-09-28 Novo Nordisk A/S Module de capteur rotatif avec caractéristique de resynchronisation
EP3177345B1 (fr) 2014-03-14 2021-11-10 SHL Medical AG Dispositif de surveillance
EP3659651A3 (fr) 2014-07-10 2020-10-14 Companion Medical, Inc. Système d'administration de médicament comprenant un stylo d'injection et un dispositif complémentaire
KR20170035969A (ko) 2014-08-19 2017-03-31 케어베이 유럽 리미티드 사용자 거동을 로깅 및 추적하기 위한 모션 검출기를 구비한 약물 주입 장치 또는 주입 모형 데모 장치
EP3045186A1 (fr) 2015-01-16 2016-07-20 Sanofi-Aventis Deutschland GmbH Capteur à utiliser avec un dispositif d'administration de médicaments
US10737029B2 (en) 2015-01-21 2020-08-11 Sanofi-Aventis Deutschland Gmbh Supplemental device for attachment to a pen injector and determination of a set dose amount using optical incremental encoder
EP3058970A1 (fr) 2015-02-19 2016-08-24 Sanofi-Aventis Deutschland GmbH Dispositif de collecte de données destiné à être fixé à un dispositif d'injection
WO2016135236A1 (fr) 2015-02-27 2016-09-01 Novo Nordisk A/S Dispositif accessoire avec élément de sécurité de montage
AU2016269688A1 (en) 2015-05-29 2018-01-18 Insulcloud, S.L. Monitoring device for drug application with a drug pen, with logging, communication and alarms
EP4316552A3 (fr) 2015-06-09 2024-04-17 Sanofi-Aventis Deutschland GmbH Appareil de collecte de données destiné à être fixé à un dispositif d'injection
EP3184137A1 (fr) 2015-12-23 2017-06-28 Carebay Europe Ltd. Dispositif d'administration de médicament avec capacité de rétroaction d'utilisateur
US20170182258A1 (en) 2015-12-29 2017-06-29 InsuLog Ltd. Adjunct device and system for an injector for monitoring injected amounts
US10857304B2 (en) 2016-03-25 2020-12-08 Eli Lilly And Company Determination of a dose set and delivered in a medication delivery device
US20190269858A1 (en) 2018-03-05 2019-09-05 Verily Life Sciences Llc Multi-channel rotary encoder

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008399B2 (en) † 2001-02-14 2006-03-07 Novo Nordisk A/S Electronically controlled device
US20140194826A1 (en) † 2011-07-07 2014-07-10 Novo Nordisk A/S Drug delivery injection pen with add-on dose capturing and display module
WO2014128156A1 (fr) † 2013-02-19 2014-08-28 Novo Nordisk A/S Module capteur rotatif à commutateur axial

Also Published As

Publication number Publication date
DK3307357T3 (da) 2020-08-03
HK1248622A1 (zh) 2018-10-19
CN107787236B (zh) 2021-06-08
JP2021112571A (ja) 2021-08-05
PL3307357T3 (pl) 2020-11-16
US11439762B2 (en) 2022-09-13
CN107787236A (zh) 2018-03-09
PL3307357T5 (pl) 2023-09-18
EP3307357A1 (fr) 2018-04-18
CN113456946A (zh) 2021-10-01
US11730891B2 (en) 2023-08-22
US20180154086A1 (en) 2018-06-07
US11944796B2 (en) 2024-04-02
US20200353176A1 (en) 2020-11-12
US11511047B2 (en) 2022-11-29
ES2805230T5 (es) 2023-11-24
CN112206381A (zh) 2021-01-12
EP4316552A2 (fr) 2024-02-07
EP3656423B1 (fr) 2024-03-13
US20240066234A1 (en) 2024-02-29
JP2018517502A (ja) 2018-07-05
CN112206381B (zh) 2023-10-27
US20230256175A1 (en) 2023-08-17
US20200384205A1 (en) 2020-12-10
EP3656423A1 (fr) 2020-05-27
ES2805230T3 (es) 2021-02-11
WO2016198516A1 (fr) 2016-12-15
DK3307357T4 (da) 2023-08-21
EP3307357B1 (fr) 2020-05-06
US10874802B2 (en) 2020-12-29
EP3656423C0 (fr) 2024-03-13
JP7162093B2 (ja) 2022-10-27
EP4316552A3 (fr) 2024-04-17
CN113456946B (zh) 2023-12-26
JP6901975B2 (ja) 2021-07-14
HUE050055T2 (hu) 2020-11-30
US20200147315A1 (en) 2020-05-14
US20220001111A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US11511047B2 (en) Data collection apparatus for attachment to an injection device
EP3503946A1 (fr) Dispositif pour la fixation à un dispositif d'injection
CN112584884B (zh) 用于附接至注射装置的数据收集设备
US20240058545A1 (en) Dosage measurement system
CN111225698B (zh) 药剂给予装置和数据收集装置
WO2021214274A1 (fr) Dispositif d'injection muni d'un détecteur électronique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248622

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191216

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1265777

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016035777

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200728

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20200506

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200402193

Country of ref document: GR

Effective date: 20201014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200907

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200906

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200806

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E050055

Country of ref document: HU

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1265777

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602016035777

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2805230

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210211

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

26 Opposition filed

Opponent name: DI-CARE ZRT.

Effective date: 20210208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230314

Year of fee payment: 8

27A Patent maintained in amended form

Effective date: 20230607

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602016035777

Country of ref document: DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230421

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20230608

Year of fee payment: 8

Ref country code: IT

Payment date: 20230510

Year of fee payment: 8

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20230817

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20200506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230608

Year of fee payment: 8

Ref country code: HU

Payment date: 20230525

Year of fee payment: 8

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230517

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230712

Year of fee payment: 8

Ref country code: CH

Payment date: 20230702

Year of fee payment: 8

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2805230

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20231124

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230401520

Country of ref document: GR

Effective date: 20231113

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240415

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240327

Year of fee payment: 9

Ref country code: FR

Payment date: 20240328

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240410

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240402

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240328

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240612

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240514

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240516

Year of fee payment: 9

Ref country code: AT

Payment date: 20240529

Year of fee payment: 9